Gut Liver.  2020 Nov;14(6):707-726. 10.5009/gnl20246.

Clinical Guidelines for Drug-Related Peptic Ulcer, 2020 Revised Edition

• Joo MK
• Park CH
• Kim JS
• Park JM
• Ahn JY
• Lee BE
• Lee JH
• Yang HJ
• Cho YK
• Bang CS
• Kim BJ
• Jung HK
• Kim BW
• Lee YC
• Korean College of Helicobacter and Upper Gastrointestinal Research

• KMID: 2508690
• DOI: http://doi.org/10.5009/gnl20246

Abstract

Korean guidelines for nonsteroidal anti-inflammatory drug (NSAID)-induced peptic ulcer were previously developed in 2009 with the collaboration of the Korean College of Helico-bacter and Upper Gastrointestinal Research and Korean So-ciety of Gastroenterology. However, the previous guidelines were based mainly upon a review of the relevant literature and expert opinion. Therefore, the guidelines need to be revised. We organized a guideline Development Commit-tee for drug-related peptic ulcer under the auspices of the Korean College of Helicobacter and Upper Gastrointestinal Research in 2017 and developed nine statements, includ-ing four for NSAIDs, three for aspirin and other antiplatelet agents, and two for anticoagulants through a de novo process founded on evidence-based medicine that included a literature search and a meta-analysis, A consensus was reached through the application of the modified Delphi method. The primary target of these guidelines is adult pa-tients undergoing long-term treatment with NSAIDs, aspirin or other antiplatelet agents and anticoagulants. The revised guidelines reflect the expert consensus and is intended to assist clinicians in the management and prevention of druginduced peptic ulcer and associated conditions.

Keyword

Peptic ulcer; Non-steroidal anti-inflammatory agents; Antiplatelet agent; Anticoagulants; Guideline